Wird geladen...
Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
Whilst the global prevalence of haemophilia B is less than that of haemophilia A, rapid and remarkable innovations have been made in the development of haemophilia B therapies in the last decade. The most recent developments are the evolution of extended half-life haemophilia B replacement therapies...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Hematol |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6196631/ https://ncbi.nlm.nih.gov/pubmed/30364483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718802606 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|